Drug Profile

AFNT 313

Alternative Names: AFNT-313; P53 R175H targeted T cell therapy - Affini-T Therapeutics

Latest Information Update: 12 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Affini-T Therapeutics
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

07 Apr 2024 Affini-T Therapeutics plans clinical trial for Solid tumours (Parenteral)
07 Apr 2024 Preclinical trials in Solid tumours in USA (Parenteral) (Affini-T Therapeutics pipeline; April 2024)
13 Jul 2022 Research programme: Mutant p53 directed T cell therapies - Affini-T Therapeutics is available for licensing as of 21 Jun 2022. https://affinittx.com/pipeline/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com